At the same time, to explore the effects of castration on prostate cancer, VCaP cells were subjected to long-term treatment with enzalutamide at either low (2 μM) or high (20 μM) concentrations for at least four weeks, and the expression of NAT10, CDC6, and AR was measured. This evidence concerns the gene NAT10 and prostate cancer.